The EMA has published an implementation plan for Europe's new pharmacovigilance legislation, which comes into force in July.
The legislation will improve the safety and risk–benefit monitoring of drugs and represents the biggest change in the EMA's
Fighting tropical diseases
Pfizer, Sanofi, GlaxoSmithKline and other major companies and global healthcare organisations have joined forces and pledged
to defeat 10 neglected tropical diseases by 2020. The companies will donate an average of 1.4 billion treatments each year,
while new collaborative R&D is expected to lead to new treatment options.
Jobs axed at AstraZeneca
AstraZeneca has announced restructuring initiatives that could lead to 7300 job losses. Positions affected include those in
selling, general and administrative areas, as well as operations and neuroscience R&D. The restructuring is expected to deliver
around $1.6 billion in annual benefits by the end of 2014.
FDA's Heparin guidance
The FDA has released a draft guidance for API manufacturers that provides recommendations for procedures to ensure that crude
heparin does not contain oversulfated chondroitin sulphates or nonporcine origin material. The guidance is titled Heparin for Drug and Medical Device Use: Monitoring Crude Heparin for Quality.